Zhao Z (2018) The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B 8(4):539–551

Article  PubMed  PubMed Central  Google Scholar 

OHSU Knitght Cancer Institute Available from: https://www.ohsu.edu/knight-cancer-institute/car-t-cell-therapy-cancer

Liu G (2021) Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol 18(5):1085–1095

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh AP et al (2020) Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. In MAbs. Taylor & Francis

Zhu H et al (1996) Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy. Cancer Res 56(16):3771–3781

CAS  PubMed  Google Scholar 

Khot A et al (2019) Measurement and quantitative characterization of whole-body pharmacokinetics of exogenously administered T cells in mice. J Pharmacol Exp Ther 368(3):503–513

Article  CAS  PubMed  PubMed Central  Google Scholar 

Owens K, Bozic I (2021) Modeling CAR T-cell therapy with patient preconditioning. Bull Math Biol 83(5):1–36

Article  Google Scholar 

Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39(1):67–86

Article  CAS  PubMed  Google Scholar 

Strati P et al (2021) Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL). J Clin Oncol 39(15suppl):7541–7541

Article  Google Scholar 

Haas AR (2019) Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther 27(11):1919–1929

Article  CAS  PubMed  PubMed Central  Google Scholar 

Therapeutics T (2020) Interim Clinical Data from Gavo-cel (TC-210) Patients. Available from: https://investors.tcr2.com/static-files/3ca4958f-17a7-4fd7-a1c3-4790d2cb9c3d

Narayan V et al (2019) A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. American Society of Clinical Oncology

Shi D (2020) Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase i trials. Clin Cancer Res 26(15):3979–3989

Article  CAS  PubMed  Google Scholar 

Ribeiro RM et al (2002) In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4 + but not CD8 + T cells depleted? Proceedings of the National Academy of Sciences, 99(24): pp. 15572–15577

Singh AP et al (2021) Bench-to‐bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic‐pharmacodynamic model: A case study with anti‐BCMA CAR‐T, vol 10. pharmacometrics & systems pharmacology, CPT, pp 362–376. 4

Google Scholar 

Watanabe K (2018) Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology. Front Immunol. https://doi.org/10.3389/fimmu.2018.02486

Article  PubMed  PubMed Central  Google Scholar 

Chan PL (2011) The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of Maraviroc in asymptomatic HIV subjects. J Pharmacokinet Pharmacodyn 38(1):41–61

Article  PubMed  Google Scholar 

Rohatgi A, Webplotdigitizer (2021) Version 4.5. ; Available from: https://automeris.io/WebPlotDigitizer

Wickham H (2016) ggplot2: elegant graphics for data analysis. Springer-, New York

Book  Google Scholar 

Schmid HP, McNeal JE, Stamey TA (1993) Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71(6):2031–2040

Article  CAS  PubMed  Google Scholar 

Patel U (2022) CAR T cell therapy in solid tumors: a review of current clinical trials. EJHaem 3:24–31

Article  PubMed  Google Scholar 

Jones H (2015) Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther 97(3):247–262

Article  CAS  PubMed  Google Scholar 

Zhang X (2020) Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018-2019 submissions to the US fda’s office of clinical pharmacology. J Clin Pharmacol 60:S160–S178

Article  PubMed  Google Scholar 

Lymphodepletion optimization for CAR T-cell therapy Available from: https://multiplemyelomahub.com/medical-information/lymphodepletion-optimization-for-car-t-cell-therapy

An C (2015) Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. Clin Mol Hepatol 21(3):279

Article  PubMed  PubMed Central  Google Scholar 

Mazaheri Y et al (2009) Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. Radiology 252(2):449–457

Article  PubMed  PubMed Central  Google Scholar 

Beaupierre A, Lundberg R, Marrero L, Jain M, Wang T, Alencar MC (2019) Management across settings: an ambulatory and community perspective for patients undergoing CAR T-cell therapy in multiple care settings. Clin J Oncol Nurs 23(2):27–34. https://doi.org/10.1188/19.CJON.S1.27-34

Article  PubMed  Google Scholar 

Neelapu SS (2019) CAR-T efficacy: is conditioning the key? Blood 133(17):1799–1800. https://doi.org/10.1182/blood-2019-03-900928

Article  CAS  PubMed  Google Scholar 

Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L (2016) RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer 62:132–137 Epub 2016 May 14. PMID: 27189322; PMCID: PMC5737828

Article  PubMed  PubMed Central  Google Scholar 

Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15(2):257–60. https://doi.org/10.1093/annonc/mdh059

Article  CAS  PubMed  Google Scholar 

Salem AM, Mugundu GM, Singh AP (2023) Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T-cell subsets and immunophenotypes in cancer patients. CPT: Pharmacometrics & Systems Pharmacology 12(9):1285–1304. https://doi.org/10.1002/psp4.13009

Article  CAS  Google Scholar 

Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, Barba P, Doglio M, Henderson D, Hudecek M, Kremer A, Markman J, Nauerth M, Negre H, Sanges C, Staber PB, Tanzi R, Delgado J, Busch DH, Kuball J, Luu M, Jäger U (2023) Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol 14:1303935. https://doi.org/10.3389/fimmu.2023.1303935

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paolo Strati et al (2021) Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL). JCO 39, 7541–7541

Demin O Jr et al (2022) Application of Semi-mechanistic Mathematicaml Modeling to Optimize Lymphodepletion Regimen Administered before Infusion of Genetically Modified T Cells. PW-014, ASCPT

Derippe T, Fouliard S, Marchiq I, Dupouy S, Almena-Carrasco M, Geronimi J, Declèves X, Chenel M, Mager DE (2022) Mechanistic modeling of the interplay between host immune system, IL-7 and UCART19 allogeneic CAR-T cells in adult B-cell acute lymphoblastic leukemia. Cancer Res Commun 2(11):1532–1544. https://doi.org/10.1158/2767-9764.CRC-22-0176

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stein AM, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Levine BL, Tomassian L, Shah S, Leung M, Huang PH, Awasthi R, Mueller KT, Wood PA, June CH (2019) Tisagenlecleucel Model-Based cellular kinetic analysis of chimeric antigen Receptor-T cells. CPT Pharmacometrics Syst Pharmacol 8(5):285–295 Epub 2019 Mar 7. PMID: 30848084; PMCID: PMC6539725

Article  CAS  PubMed  PubMed Central  Google Scholar